Moneycontrol PRO
HomeNewsBusinessStocksSun Pharma gains, brokerages bet on Taro's performance

Sun Pharma gains, brokerages bet on Taro's performance

Investors continued to buy shares of Sun Pharmaceutical Industries on Tuesday after CLSA has retained its high conviction buy rating on the stock with a target of Rs 1,130.

May 05, 2015 / 14:29 IST
     
     
    26 Aug, 2025 12:21
    Volume
    Todays L/H
    More

    Moneycontrol Bureau

    Investors continued to buy shares of Sun Pharmaceutical Industries Tuesday as brokerages bet on its subsidiary Taro's performance. The stock gained 1.5 percent intraday.

    With retaining high conviction buy on Sun (with target of Rs 1,130), CLSA said Taro Pharma’s contribution to Sun’s profits is likely to remain high at 25 percent despite fall in sales growth and margin contribution.

    In a bear case, the brokerage expects Taro’s sales growth in single-digits and margins at 50 percent (65 percent currently) by FY17.

    Meanwhile, CreditSuisse has maintained its outperform rating as the brokerage believes new set of price increases will boost Taro's EBITDA by 4 percent.

    Taro has pushed through price increase in two products - Enalapril Maleate (treats high blood pressure), and Econazole nitrate cream (antifungal medication). According to Credit Suisse, both the drugs together could add incremental sales of USD 20-25 million and boost Taro's current run-rate of sales by 3 percent and EBITDA by 4 percent.

    Taro is the industry leader in the highly concentrated, high-entry-barrier US generic derma market. Taro derives around 65 percent of its sales from products approved in the 1990s where no fresh entrant has received an approval in the last five years.

    Taro, which is owned by Sun Pharma with 69 percent equity stake, has taken around 86 percent price increase on average product portfolio starting CY11. Taro has a 17 percent market share in the USD 5 billion US generic derma market (growing at 6 percent CAGR) while the top 6 generics account for 70 percen of the market.

    Taro has filed 29 abbreviated new drug applications (ANDA) in the last three years which could be approved over the next 4-5 years.

    At 11:22 hours IST, the scrip of Sun Pharmaceutical Industries was quoting at Rs 958.00, up Rs 11.65, or 1.23 percent on the BSE.

    Posted by Sunil Shankar Matkar

    first published: May 5, 2015 02:29 pm

    Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

    Subscribe to Tech Newsletters

    • On Saturdays

      Find the best of Al News in one place, specially curated for you every weekend.

    • Daily-Weekdays

      Stay on top of the latest tech trends and biggest startup news.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347